LOBEF Stock Chart & Stats
$0.06
<$0.01(4.00%)
At close: 4:00 PM EDT
$0.06
<$0.01(4.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume1.56K
Average Volume (3M)97.66K
Market Cap
$9.92M
Enterprise Value$25.61M
Total Cash (Recent Filing)$5.21M
Total Debt (Recent Filing)$338.40K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding308,182,160
10 Day Avg. Volume126,666
30 Day Avg. Volume97,663
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market Cap2.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.26
Revenue Forecast (FY)$8.37M
Bulls Say, Bears Say
Bulls Say
Equity StabilizationThe return to positive equity marks a meaningful improvement from the company’s earlier balance-sheet weakness. Although capital remains volatile, this stabilization provides a stronger base for financing, partnerships, and continued development than the negative-equity position reported in prior years.
Modest Absolute DebtRelatively low absolute debt limits the fixed obligations directly burdening the business and reduces dependence on substantial interest-bearing financing. This offers some financial flexibility while the company works to develop operations, even though shrinking equity makes leverage more significant.
Prior Gross Profit PotentialThe strong FY2024 gross-profit share indicates that the company previously demonstrated potentially attractive economics on the revenue it generated. If commercial activity is re-established, that historical margin profile could support operating leverage, although current zero revenue means it is not presently being realized.
Bears Say
No Current RevenueThe absence of current revenue shows that Lobe Sciences does not presently have a functioning commercial revenue base supporting its operations. This weakens visibility into future self-funded growth and leaves successful development, commercialization, or partnering as essential to rebuilding durable earnings capacity.
Worsening Operating LossesWidening operating losses despite zero revenue indicate that the company continues consuming resources without corresponding commercial output. Persistent losses can erode the capital base, constrain investment in development, and increase the likelihood that future progress requires external financing.
Increasing Cash BurnCash generation is materially negative and has deteriorated from the prior fiscal year, demonstrating limited ability to fund operations internally. Continued burn raises financing risk over the medium term and may force the company to prioritize capital preservation over research, development, or commercialization efforts.
Lobe Sciences News
LOBEF FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was $0.02 and its highest was $0.11 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is $9.92M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Dec 18, 2026 which is in 48 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Jul 30, 2026. The company reported -$0.001 earnings per share for the quarter.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 308,182,160 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -$0.001 in its last earnings report. Following the earnings report the stock price went up 18.644%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in LOBEF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―